You are here

W. magna, 90% efficacy on mildew

Lyon, 4th Mai 2018 AMOEBA announces today the first greenhouse test results conducted with the microorganism, Willaertia magna C2c Maky, used as a biocontrol agent for the control of mildew on grapevine.

 The results of the first greenhouse trials show very clear dose-responses of Willaertia magna C2c Maky in a formulated product. The efficacy of more than 90% of the formulated product on mildew has to be compared to the usual efficacy of biocontrol agents of around 50% observed in greenhouses. A new series of tests is scheduled in 2018 in preparation of the field trials planned in 2019. 

Willaertia Magna as a biocontrol agent

Lyon, November 22nd, 2017- AMOEBA announced today the positive results of in vitro trials conducted with Willaertia Magna C2c Maky microorganism for the control of plant diseases.

Those in vitro trials were carried out by the company CONIDIA, recognized for its broad expertise in fungi and their resistance to fungicides.

New LOI in Switzerland

Lyon (France), Lancy (Switzerland), November 8th, 2017 - AMOEBA announced today that it has signed a Letter of Intent (LOI) with H2O FACILITIES prior to entering into a definitive agreement regarding the distribution of its product in Switzerland, pending marketing authorization.

EIB provides EUR 20m credit line to Amoéba

Lyon, October 9th, 2017 - Amoéba has received financing worth EUR 20m from the EIB. This EIB financing is secured by the European Fund for Strategic Investments (EFSI), the cornerstone of the Investment Plan for Europe, commonly known as the Juncker Plan.

3rd distribution agreement in Europe

Lyon (France), Rome, September 14th, 2017 - AMOEBA announced today that it has signed a distribution agreement for its BIOMEBA product with DREWO. This agreement is pending marketing authorization (MA) in Italy.

The collaboration between DREWO and AMOEBA started in November 2015 with the signature of a Letter of Intention (LOI). In August 2016, both companies carried out a first field test in Italy for an industrial company in the automotive sector. This test, still ongoing today, has confirmed the effectiveness of BIOMEBA. Following this success, this car manufacturer wishes to start a new field test on another industrial site before the end of the year. Meanwhile, a second test has started in January 2017 with a client of DREWO from the food industry.

Amoéba will be at AWT 2017

Lyon, Friday 25th August 2017 – For the 3rd consecutive year Amoéba will participate at the annual exhibition of industrial water treatment specialists in the United States organized by AWT, Association of Water Technologies. During this event, Amoéba will present its biological biocide BIOMEBA to US water treater.

LOI signature on new US territory

Lyon (France), Atlanta (GA, USA), July 27th, 2017 – Amoéba announced today that it has signed a Letter of Intent (LOI) with MOMAR Inc. prior to entering into a definitive agreement regarding the distribution of its product in the United States pending marketing authorization. The signature of this agreement allows AMOEBA to extend its commercial cover for the distribution of the green biocide BIOMEBA on the South-East states of the United States including mainly agri-food and aerospace industries.

Fabrice Plasson elected to WssTP

Fabrice Plasson, CEO of Amoéba, was elected at the new board of the WssTP’s, for the period 2017-2019. He’ll be representing College D: Suppliers & SME’s.  The election took place during the WssTP Annual general meeting held during the Water Innovation Europe 2017 conference on 14th June 2017.

Collaboration for wound care treatment

Lyon, Cleveland, June 27th, 2017 - AMOEBA announced today the development of a collaboration with VISCUS BIOLOGICS in order to carry out collective testing on a new wound care application in the field of human health.

VISCUS BIOLOGICS has a proven expertise in the field of wound care products, in particular collagen-based dressings. Following preliminary in vitro testing, the two companies intend to extend their cooperation and further confirm, through additional in vitro and in vivo testing, the action of the Willaertia magna C2c Maky micro-organism against certain pathogenic Multi-Drug Resistant (MDR) bacteria that resist multiple antibiotics.  Willaertia magna C2c Maky could therefore be used with advanced wound care dressings. This project is in the first instance focusing on the US market.

1st distribution agreement in USA

Lyon, France & Chicago, USA, May 22nd, 2017 – Amoéba announced today the signature with Earthwise Environmental of the first Distribution Agreement in the USA for its BIOMEBA product. This agreement covers the territory of Texas, Oklahoma, Illinois, Indiana, and Wisconsin.